Head-to-head evidence
Iloprost vs Treprostinil (Yutrepia, Liquidia)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Hypertension pipeline
Iloprost · Ventavis
Marketed by Johnson & Johnson and partners
NCT01469169 · Phase 3 · completed
This was a small, single-group, open-label study with no randomized control or comparator arm, and its primary efficacy measure—change in pulmonary vascular resistance—was a hemodynamic surrogate rather than a direct clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT07759804 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Iloprost's landscape · Treprostinil (Yutrepia, Liquidia)'s landscape